Abstract: A method for operating a medical fluid machine, the method comprising: (i) if alternating current (“AC”) power is available, charging a battery, if needed, and powering the medical fluid machine with the AC power; and (ii) if AC power is not available (a) if fuel cell power is available, charging the battery, if needed, and powering the medical fluid machine with the fuel cell power; and (b) if fuel cell power is not available, powering the medical fluid machine using battery power until the AC power or fuel cell power is available.

Abstract: Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone.

Abstract: The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

Abstract: A method for priming a hemodialysis treatment includes: providing a sorbent cartridge for cleaning spent dialysate fluid returning from a dialyzer; preparing a batch of dialysate in a quantity commensurate with being recycled through the sorbent cartridge multiple times; priming a dialysate circuit in fluid communication with the dialyzer using the batch of dialysate; and priming a blood circuit in fluid communication with the dialyzer using the batch of dialysate.

Abstract: A hemodialysis system includes: a peristaltic blood pump; a first peristaltic dialysate pump; a second peristaltic dialysate pump; and a fluid cassette including an upper portion and a lower portion, a blood pumping tube extending linearly from the upper portion to the lower portion, the blood pumping tube actuated by the peristaltic blood pump, a first dialysate pumping tube extending linearly from the upper portion to the lower portion, the first dialysate pumping tube actuated by the first dialysate pump, and a second dialysate pumping tube extending linearly from the upper portion to the lower portion, the second dialysate pumping tube actuated by the second dialysate pump.

Abstract: Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest.

Abstract: The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.

Abstract: The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.

Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.

Abstract: A medical fluid system including: fluid containers and a tube extending from same, each tube including a cap; a pumping cassette including port spikes; a medical fluid machine including: occluders; a shuttle configured to receive the tubes, wherein each tube is associated with one of the occluders; a driving mechanism translating the shuttle; a cap removal device between the cassette and the shuttle; and a control unit programmed to cause: (i) the occluders to pinch their tubes, (ii) cause the driving mechanism to translate the shuttle towards the fluid pumping cassette, the cap removal device engaging the tube caps, (iii) the driving mechanism to translate the shuttle away from the fluid pumping cassette and cap removal device, pulling the tube caps off of the tubes, and (iv) the driving mechanism to translate the shuttle back towards the fluid pumping cassette for the port spikes to spike the occluded tubes.

Abstract: A priming indicator for a fluid infusion system includes a luer cap or other component of the infusion system having an indicator surface covered by a membrane. The membrane exhibits a first visual characteristic, such as being opaque, when dry and exhibits a second characteristic, such as becoming less opaque, when wet. Once the membrane becomes wet, indicia on the surface, which may be provided on a rod at least partially covered by the membrane, becomes visible, thereby indicating an intravenous tube to which the luer cap is secured has been primed or is nearly primed. The indicator may alternately be employed at an upstream end of an infusion set, such as at the port of a medical bag providing a supply of fluid, to indicate a low level of fluid in the medical bag.

Abstract: Transfer sets are disclosed in the present patent. The transfer set provides a connection between a source of peritoneal dialysis fluid and a patient for whom peritoneal dialysis has been prescribed. The transfer sets disclosed herein are smaller and provide a more compact and convenient device by which a dialysis patient controls the flow of dialysis fluid to and from the peritoneum of the patient. The devices are more compact and convenient because they include more convenient mechanisms for starting and stopping flow of the dialysis fluid. It is also easy to determine whether the mechanism is in a closed or open configuration by simply looking at the mechanism.

Abstract: A method of operating a disposable pumping unit includes enabling the disposable pumping unit to be loaded into a peritoneal dialysis hardware unit between a door and a housing of the hardware unit; structuring the disposable pumping unit to have a fluid pump receptacle, the fluid pump receptacle constructed and arranged to extend from both surfaces of the unit so as to fit within a first opening provided in the door and a second opening provided in the housing of the hardware unit; and enabling the disposable pumping unit to be guided into the hardware unit such that the fluid pump receptacle becomes aligned with the opposing first and second openings when the door is closed against the housing.

Abstract: The invention discloses a method for producing a hemostatic composition comprising mixing a biocompatible polymer suitable for use in hemostasis and a genipin-type crosslinker, crosslinking said polymer by said genipin-type crosslinker to obtain a crosslinked biocompatible polymer, and finishing said crosslinks polymer to a pharmaceutically acceptable hemostatic composition, new hemostatic compositions and methods for using such compositions.

Abstract: A regenerative peritoneal dialysis system includes a dialysis fluid loop; a filter located in the dialysis fluid loop, a first portion of the dialysis fluid sent to the filter rejected by the filter and returned upstream of the filter, a second portion of the dialysis fluid sent to the filter forming permeate, the permeate being rich in urea; and a urea removing apparatus located in the dialysis fluid loop downstream from the filter to receive the permeate and absorb urea from the permeate.

Abstract: A monitor for an extracorporeal therapy access site is disclosed. The monitor includes a bandage atop or adjacent the access site and a sensor for monitoring the bandage. The bandage includes a layer of polymer that expands when wetted with blood. The expansion causes a break in continuity of the sensor, or in an alternate embodiment, causes a sensor to cease detecting a target. When the break occurs, the control circuit monitoring the bandage sends a signal that a break has occurred, and a remote monitor then takes appropriate action, such as ceasing therapy, sending an alert, or sounding an alarm. In another embodiment, connecting wires in a continuity circuit are held apart by a polymer that dissolves when contacted by blood. If a leak occurs and a small portion of the polymer dissolves, the wires make contact, thus detecting a blood leak.

Abstract: An infusion pump includes: a housing, a pump actuator supported by the housing, electronics configured to control the pump actuator, a pain controlled analgesic (“PCA”) input device, a cord having a remote end connected to the PCA input device and a local end connected to the housing, a remote integrated circuit; and a local integrated circuit in communication with the electronics and the remote integrated circuit so as to provide operational information concerning the PCA input device to the electronics.

Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.

Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.